- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Submit a Manuscript
- Table of Contents
Volume 2013 (2013), Article ID 753427, 13 pages
Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration
1Immunovaccine Inc., Division of Immunology, 1344 Summer Street, Halifax, NS, B3H 0A8, Canada
2Department of Microbiology and Immunology, Dalhousie University, 5850 College Street, Halifax, NS, B3H 4R2, Canada
Received 15 January 2013; Accepted 6 February 2013
Academic Editors: T. T. Trangas and Y. Yamamoto
Copyright © 2013 Mohan Karkada et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- J. King, J. Waxman, and H. Stauss, “Advances in tumour immunotherapy,” QJM, vol. 101, no. 9, pp. 675–683, 2008.
- O. J. Finn, “Molecular origins of cancer: cancer immunology,” The New England Journal of Medicine, vol. 358, no. 25, pp. 2704–2715, 2008.
- S. Pejawar-Gaddy and O. J. Finn, “Cancer vaccines: accomplishments and challenges,” Critical Reviews in Oncology/Hematology, vol. 67, no. 2, pp. 93–102, 2008.
- T. Sasada, N. Komatsu, S. Suekane, A. Yamada, M. Noguchi, and K. Itoh, “Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines,” European Journal of Cancer, vol. 46, no. 9, pp. 1514–1519, 2010.
- S. H. van der Burg, M. S. Bijker, M. J. P. Welters, R. Offringa, and C. J. M. Melief, “Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy,” Advanced Drug Delivery Reviews, vol. 58, no. 8, pp. 916–930, 2006.
- S. A. Rosenberg, J. C. Yang, and N. P. Restifo, “Cancer immunotherapy: moving beyond current vaccines,” Nature Medicine, vol. 10, no. 9, pp. 909–915, 2004.
- T. Lanca and B. Silva-Santos, “The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy,” Oncoimmunology, vol. 1, no. 5, pp. 717–725, 2012.
- M. Beyer and J. L. Schultze, “Regulatory T cells in cancer,” Blood, vol. 108, no. 3, pp. 804–811, 2006.
- T. J. Curiel, “Regulatory T cells and treatment of cancer,” Current Opinion in Immunology, vol. 20, no. 2, pp. 241–246, 2008.
- S. J. Piersma, M. J. P. Welters, and S. H. van der Burg, “Tumor-specific regulatory T cells in cancer patients,” Human Immunology, vol. 69, no. 4-5, pp. 241–249, 2008.
- S. Nagaraj and D. I. Gabrilovich, “Tumor escape mechanism governed by myeloid-derived suppressor cells,” Cancer Research, vol. 68, no. 8, pp. 2561–2563, 2008.
- S. Ostrand-Rosenberg and P. Sinha, “Myeloid-derived suppressor cells: linking inflammation and cancer,” Journal of Immunology, vol. 182, no. 8, pp. 4499–4506, 2009.
- J. E. Talmadge, “Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy,” Clinical Cancer Research, vol. 13, no. 18, part 1, pp. 5243–5248, 2007.
- G. Lizée, L. G. Radvanyi, W. W. Overwijk, and P. Hwu, “Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms,” Clinical Cancer Research, vol. 12, no. 16, pp. 4794–4803, 2006.
- B. Liu, J. Nash, C. Runowicz, H. Swede, R. Stevens, and Z. Li, “Ovarian cancer immunotherapy: opportunities, progresses and challenges,” Journal of Hematology and Oncology, vol. 3, article 7, 2010.
- F. Pagès, A. Berger, M. Camus et al., “Effector memory T cells, early metastasis, and survival in colorectal cancer,” The New England Journal of Medicine, vol. 353, no. 25, pp. 2654–2666, 2005.
- P. Daftarian, M. Mansour, A. C. Benoit et al., “Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion,” Vaccine, vol. 24, no. 24, pp. 5235–5244, 2006.
- P. M. Daftarian, M. Mansour, B. Pohajdak et al., “Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax encapsulated CTL/T helper peptides,” Journal of Translational Medicine, vol. 5, article 26, 2007.
- M. Mansour, B. Pohajdak, W. M. Kast et al., “Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax,” Journal of Translational Medicine, vol. 5, article 20, 2007.
- N. L. Berinstein, M. Karkada, M. A. Morse et al., “First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients,” Journal of Translational Medicine, vol. 10, no. 1, article 156, 2012.
- M. Karkada, G. M. Weir, T. Quinton et al., “A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not treg/tr1-type responses,” Journal of Immunotherapy, vol. 33, no. 3, pp. 250–261, 2010.
- V. Ramakrishna, M. M. Ross, M. Petersson et al., “Naturally occuring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells,” International Immunology, vol. 15, no. 6, pp. 751–763, 2003.
- C. L. Slingluff Jr., G. Yamshchikov, P. Neese et al., “Phase I trial of a melanoma vaccine with gp100280-288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes,” Clinical Cancer Research, vol. 7, no. 10, pp. 3012–3024, 2001.
- R. Wang, Q. Wan, L. Kozhaya, H. Fujii, and D. Unutmaz, “Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression,” PLoS One, vol. 3, no. 7, Article ID e2705, 2008.
- V. Appay, D. C. Douek, and D. A. Price, “CD8+ T cell efficacy in vaccination and disease,” Nature Medicine, vol. 14, no. 6, pp. 623–628, 2008.
- T. L. Whiteside, “The tumor microenvironment and its role in promoting tumor growth,” Oncogene, vol. 27, no. 45, pp. 5904–5912, 2008.
- H. Kobayashi and E. Celis, “Peptide epitope identification for tumor-reactive CD4 T cells,” Current Opinion in Immunology, vol. 20, no. 2, pp. 221–227, 2008.
- P. R. Dunbar, C. L. Smith, D. Chao et al., “A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response,” Journal of Immunology, vol. 165, no. 11, pp. 6644–6652, 2000.
- E. Sato, S. H. Olson, J. Ahn et al., “Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 51, pp. 18538–18543, 2005.
- F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 8, pp. 711–723, 2010.
- L. Vence, A. K. Palucka, J. W. Fay et al., “Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 52, pp. 20884–20889, 2007.
- H. Y. Wang, D. A. Lee, G. Peng et al., “Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy,” Immunity, vol. 20, no. 1, pp. 107–118, 2004.
- G. Zhou, C. G. Drake, and H. I. Levitsky, “Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines,” Blood, vol. 107, no. 2, pp. 628–636, 2006.
- S. H. van der Burg, S. J. Piersma, A. de Jong et al., “Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 29, pp. 12087–12092, 2007.
- M. J. P. Welters, G. G. Kenter, S. J. Piersma et al., “Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine,” Clinical Cancer Research, vol. 14, no. 1, pp. 178–187, 2008.
- L. Dolcetti, E. Peranzoni, S. Ugel et al., “Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF,” European Journal of Immunology, vol. 40, no. 1, pp. 22–35, 2010.
- D. Q. Tran, J. Andersson, R. Wang, H. Ramsey, D. Unutmaz, and E. M. Shevach, “GARP (LRRC32) is essential for the surface expression of latent TGF-β on platelets and activated FOXP3+ regulatory T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 32, pp. 13445–13450, 2009.
- J. M. Haverkamp, S. A. Crist, B. D. Elzey, C. Cimen, and T. L. Ratliff, “In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site,” European Journal of Immunology, vol. 41, no. 3, pp. 749–759, 2011.